FOLH1 and prostate cancer: The evaluation comprised 8 research studies, with a sensitivity of 0.56 (95% CI:0.41-0.71) in identifying ECE of prostate cancer through 68Ga-PSMA PET, whereas mpMRI demonstrated an overall sensitivity of 0.57 (95% CI:0.43-0.71) (Figure 3).